Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Hematologic Neoplasms 2Graft vs Host Disease 2Stomatitis 1Leukemia, Myeloid, Acute 1Leukemia 1High Risk Myeloid Malignancies 1

Interventions

Azacitidine 66venetoclax 21Decitabine 16Cytarabine 12decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 7fludarabine 6pevonedistat 5mocetinostat 5ON 01910 5Busulfan 5treosulfan 4sabatolimab 4ruxolitinib 4cedazuridine 4cc-486 4Mycophenolic Acid 4Lenalidomide 4Injections 4plerixafor 3luspatercept 3imetelstat 3glasdegib 3fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3GRN163L peptide 3Clofarabine 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic Syndromes × Transplantation Conditioning × Clear all
NCT04395092 2021-06-22

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Kiadis Pharma

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡